chevron_leftBack
As of 13 June 2026, Canton Strategic Holdings, Inc. has a market cap of $176.77M USD, ranking #21846 globally and #3534 in the United States.
It ranks #1963 in the Healthcare sector, and #383 in the Biotechnology industry.
Key Stats
Market Cap
$176.77MUSD
Enterprise Value
$160.02MUSD
Net Income (TTM)
-$35.92MUSD
PB Ratio
0.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Mark Wendland
open_in_new
Employees
12
Founded
2017
IPO
12 Jan 2022
Website
cantonstrategic.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -5.5% | -6.3% | -1.9% | -23% | 6.1% | 129% |
News
Loading...
THAR Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
THAR
Tharimmune Inc
ISIN: US4327053090
Shares Out.:
Shares Outstanding:
39.53M1
Shares Float:
31.837M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.12 USD | |
|
THAR
Tharimmune Inc
ISIN: US4327053090
|
76.33 MXN |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Canton Strategic Holdings, Inc.
Canton Strategic Holdings, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. The company also involved in research and development of GV104, a buccal film technology, which has completed Phase 1 trial for respiratory and/or nervous system depression in military personnel and chemical incident responders; and GV023, an oral formulation of infliximab, addresses a critical limitation of the IV gold standard by eliminating the treatment burden of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was founded in 2017 and is based in Red Bank, New Jersey.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
103K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
90K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
16K%
|
-
|
|
NYSE: IQV
|
$26.3B
15K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
14K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
10K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
27K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
25K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
24K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
24K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
16K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
14K%
|
-
|
chevron_leftBack